Navigation Links
Animal study reveals new target for antidepressants
Date:5/31/2010

Ann Arbor, Mich. University of Michigan scientists have provided the most detailed picture yet of a key receptor in the brain that influences the effectiveness of serotonin-related antidepressants, such as Prozac.

The findings, which appear online Monday ahead of print in the journal Proceedings of the National Academy of Sciences, open the door to providing a more targeted treatment of depression and anxiety with fewer side effects.

Depressive disorders change a person's mood, emotions and physical well-being and can co-occur with anxiety disorders and substance abuse.

"There are big drawbacks in the current therapies for depression," says senior author John Traynor, Ph.D., professor of pharmacology at the U-M Medical School and director of the U-M Substance Abuse Research Center. "Therapeutic benefits are delayed, there are unwanted side effects, and it's not unusual for depressive symptoms to return."

Authors say the high relapse rate indicates a need for additional treatment options for the estimated 20.9 million Americans with depression.

The best current treatments for depression are selective serotonin reuptake inhibitors, or SSRIs. These drugs work by flooding the brain's synapses with serotonin, a neurotransmitter linked with mood, and increasing signaling through the more than 20 serotonin receptors in the brain.

However the team of researchers showed that one particular pathway, the serotonin 5HT1a receptor is linked with antidepressive and antianxiety behavior in mice.

"Rather than activating all serotonin receptors as SSRIs do, one could increase signaling through the one critical serotonin receptor that our research shows is important for anti-depressant behavior," says co-author Richard R. Neubig, M.D., Ph.D., co-director of the U-M Center for Chemical Genomics and professor of pharmacology at the U-M Medical School.

The new research details the complex actions of a family of proteins, known as RGS proteins, that act as brakes on neurotransmitter signaling.

Researchers created a mutant mouse to boost serotonin signaling at the 5HT1a receptor. This was done by genetically inhibiting the activity of braking proteins. Without the normal brake on serotonin signaling, these mutant mice showed antidepressive behavior even without being given antidepressant drugs. The mice were also more responsive to SSRIs.

Authors say that further research could lead to drugs capable of inhibiting the RGS proteins and which would target the antidepressant signal where it is required on critical 5HT1a receptors.


'/>"/>

Contact: Shantell M. Kirkendoll
smkirk@umich.edu
734-764-2220
University of Michigan Health System
Source:Eurekalert

Related biology news :

1. Study sheds light on how marine animals survive stress
2. Queens researchers reveal parasitic threat to animals and the environment
3. Massive resources now directed at sustainable animal waste technology
4. Animals talk, sing and act like humans?
5. Capitol Hill briefing to focus on Denmarks ban on routine antibiotic use in food animal production
6. Grapes reduce risk factors for heart disease and diabetes, U-M animal study shows
7. Animal feed and automobiles make the San Joaquin Valley a smog hotspot
8. Poultry research leads to breakthrough in genetic studies of animal domestication
9. Animal feed, not automobiles, makes the San Joaquin Valley a smog hotspot
10. Explorers census hard-to-see sea life: microbes, tiny animals key to Earths food, carbon systems
11. Hawaiian submarine canyons are hotspots of biodiversity and biomass for seafloor animal communities
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/6/2017)... -- Forecasts by Product Type (EAC), Biometrics, ... (Transportation & Logistics, Government & Public Sector, Utilities / ... Facility, Nuclear Power), Industrial, Retail, Business Organisation (BFSI), Hospitality ... looking for a definitive report on the $27.9bn Access ... ...
(Date:4/4/2017)... YORK , April 4, 2017   EyeLock ... today announced that the United States Patent and Trademark ... patent broadly covers the linking of an iris image ... same transaction) and represents the company,s 45 th ... latest patent is very timely given the multi-modal biometric ...
(Date:3/30/2017)... Trends, opportunities and forecast in this market ... (fingerprint, AFIS, iris recognition, facial recognition, hand geometry, vein ... use industry (government and law enforcement, commercial and retail, ... others), and by region ( North America ... Pacific , and the Rest of the World) ...
Breaking Biology News(10 mins):
(Date:8/16/2017)... ... 2017 , ... While art and science are often thought of as two ... think. A Mesh Is Also a Snare, a group exhibition presented by the ... Klein Gallery (EKG) on August 17 and run through September 30. An opening reception ...
(Date:8/16/2017)... ... 2017 , ... We are proud to announce the successful ... Dilworth, MN site. The inspection took place Monday, July 31st through Friday, August ... a routine Bioresearch Monitoring Program (BIMO) with the USFDA wherein multiple Dermatology Vasoconstriction ...
(Date:8/16/2017)... , Aug. 16, 2017  Kingfisher Talent, the ... leadership development, and Virdis Group, global executive search specialists in ... that enables clients to leverage the expertise and reach of ... clients here in the Boston biotech ... of leadership talent throughout the US, Canada ...
(Date:8/15/2017)... ... 2017 , ... Kapstone Medical is proud to announce that it ... companies and inventors develop and safeguard their latest innovations. The company has grown ... portfolio of clients in the United States and around the world. , Company ...
Breaking Biology Technology: